Ascendis Pharma A/S
ASND | NASDAQ
$249.39
-$1.88 (-0.75%)
Nov 2, 2026, 10:59 AM ET · Market open
Company Profile
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Key Executives
| Name | Position |
|---|---|
| Jan Moller Mikkelsen | President, Chief Executive Officer, Member of Executive Board & Executive Director |
| Michael Wolff Jensen | Executive Vice President, Chief Legal Officer & Member of the Executive Board |
| Scott T. Smith | Chief Financial Officer, Executive Vice President & Member of Executive Board |
| Chad Fugure | Vice President of Investor Relations |
| Flemming Steen Jensen | Executive Vice President of Product Supply & Quality |
| Joseph Kelly | Head of U.S. Commercial of Endocrinology |
| Kennett Sprogoe | Executive Vice President and Head of Research & Product Development |
| Mads Bodenhoff | Senior Vice President, Head of Finance & Principal Accounting Officer |
| Pedersen Anni Lotte Kirstine Sonderbjerg | Executive Vice President, Chief Administrative Officer & Member of the Executive Board |
| Sherrie Glass | Chief Business Officer |
Ascendis Pharma A/S
| Country | Denmark |
| IPO Date | Jan 28, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,189 |
| CEO | Jan Moller Mikkelsen |
Contact Details
Tuborg Boulevard 12 Hellerup,
CR 2900 Denmark
Stock Details
| Ticker Symbol | ASND |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001612042 |
| CUSIP Number | K08588103 |
| ISIN Number | DK0060615755 |
| SIC Code | 2834 |
Recent News
- 7 days ago / globenewswire.comTransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
- 17 days ago / globenewswire.comOnce-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
- 26 days ago / zacks.comFDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
- 27 days ago / globenewswire.comAscendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
- 2 months ago / seekingalpha.comAscendis Pharma: Back To Full Independence
- 2 months ago / seekingalpha.comAscendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / benzinga.comWhy Is Ascendis Pharma Stock Trading Lower on Tuesday?
- 2 months ago / globenewswire.comAscendis Announces Planned $400 Million Share Repurchase Program
- 2 months ago / globenewswire.comAscendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
- 2 months ago / globenewswire.comAscendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
Add to Watchlist
Select watchlists to add or remove ASND